Janssen Biotech Inc., a Johnson &amp; Johnson (JNJ) company, announced today that it had inked a global collaboration and licensing agreement with Rockville, Md.-based MacroGenics, Inc (MGNX). The deal focuses on MGD011, a humanized CD19 x CD3 bispecific DART protein that has potential for the treatment of B-cell hematological malignancies.